Clinical Endoscopy

  • 제44권1호
  • /
  • Pages.33-37
  • /
  • 2011
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection

  • Park, Hyun-Kyung (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Dong-Ho (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Suh, Seung-Chul (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Seo, Pyoung-Ju (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Na-Young (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Jeong, Sook-Hyang (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jin-Wook (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Hwang, Jin-Hyeok (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Park, Young-Soo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Sang-Hyub (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Shin, Cheol-Min (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • 발행 : 2011.09.30
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection. Methods: From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the $^{13}C$ urea breath test at least 6 weeks after treatment. Results: The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort. Conclusions: A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

키워드

참고문헌

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186. https://doi.org/10.1056/NEJMra020542
  2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. https://doi.org/10.1136/gut.2006.101634
  3. Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol 2006;48:156-161.
  4. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170-175.
  5. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009;14:77-85.
  6. Perri F, Festa V, Clemente R, et al. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
  7. Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-319. https://doi.org/10.1046/j.1523-5378.2003.00158.x
  8. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395-403. https://doi.org/10.1111/j.1365-2036.2006.02993.x
  9. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x
  10. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057. https://doi.org/10.1046/j.1365-2036.2002.01276.x
  11. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283-285. https://doi.org/10.1093/jac/46.2.283
  12. Tanaka M, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002;49:1039-1040. https://doi.org/10.1093/jac/dkf055
  13. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol 2006;47:337-349.
  14. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003;8:90-94. https://doi.org/10.1046/j.1523-5378.2003.00128.x
  15. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000;14:311-316. https://doi.org/10.1046/j.1365-2036.2000.00719.x
  16. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999;43:1497-1499.
  17. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. Aliment Pharmacol Ther 2001;15:143. https://doi.org/10.1046/j.1365-2036.2001.00909.x
  18. Bayerdörffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-1417. https://doi.org/10.1016/0016-5085(95)90689-4
  19. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdörffer E. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323-329. https://doi.org/10.1046/j.1365-2036.1997.140316000.x
  20. Lamouliatte H, Cayla R, Zerbib F, et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. Am J Gastroenterol 1998;93:1531-1534. https://doi.org/10.1111/j.1572-0241.1998.00280.x
  21. Westblom TU, Duriex DE. Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections. Dig Dis Sci 1991;36:25-28. https://doi.org/10.1007/BF01300082
  22. Kim JJ, Reddy R, Lee M, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001;47:459-461. https://doi.org/10.1093/jac/47.4.459
  23. Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19:789-795. https://doi.org/10.1111/j.1365-2036.2004.01910.x
  24. Nam TM, Lee DH, Kang KP, et al. Clinical factors that potentially affect the treatment outcome of Helicobacter pylori eradication therapy with using a standard triple regimen in peptic ulcer patients. Korean J Gastrointest Endosc 2008;36:200-205.
  25. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384. https://doi.org/10.1136/gut.2003.022111
  26. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-654. https://doi.org/10.1046/j.1365-2036.2003.01746.x
  27. Keum B, Lee SW, Kim SY, et al. Comparison of Helicobacter pylori eradication rate according to different PPI-based triple therapy: omeprazole, rabeprazole, esomeprazole and lansoprazole. Korean J Gastroenterol 2005;46:433-439.
  28. de Boer WA, Tytgat GN. Regular review: treatment of Helicobacter pylori infection. BMJ 2000;320:31-34. https://doi.org/10.1136/bmj.320.7226.31
  29. Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis 2003;35:357-361. https://doi.org/10.1016/S1590-8658(03)00081-1
  30. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001;15:1543-1547. https://doi.org/10.1046/j.1365-2036.2001.01064.x
  31. Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000;14:1335-1338. https://doi.org/10.1046/j.1365-2036.2000.00833.x

피인용 문헌

  1. Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis vol.30, pp.8, 2011, https://doi.org/10.3346/jkms.2015.30.8.1001
  2. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience vol.63, pp.2, 2011, https://doi.org/10.1007/s10620-017-4880-8